Immix Biopharma (IMMX) Cash & Equivalents (2020 - 2026)

Immix Biopharma (IMMX) has 7 years of Cash & Equivalents data on file, last reported at $79.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 397.77% year-over-year to $79.3 million; the trailing twelve-month figure through Mar 2026 stood at $79.3 million (up 397.77% YoY), and the FY2025 full-year result was $93.9 million, up 431.21% from the prior year.
• Cash & Equivalents fell to $79.3 million in Q1 2026, from $93.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $93.9 million in Q4 2025 to a low of $11.5 million in Q1 2023.
• A 5-year average of $25.7 million and a median of $17.7 million in 2024 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 431.21% in 2025, while the deepest fall reached 51.62% in 2025.
• Tracing IMMX's Cash & Equivalents over 5 years: stood at $13.4 million in 2022, then surged by 30.31% to $17.5 million in 2023, then climbed by 0.98% to $17.7 million in 2024, then jumped by 431.21% to $93.9 million in 2025, then decreased by 15.63% to $79.3 million in 2026.
• Business Quant data shows IMMX's Cash & Equivalents at $79.3 million in Q1 2026, $93.9 million in Q4 2025, and $15.9 million in Q3 2025.